Literature DB >> 23324537

Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization.

Charles E Mahan1, Alex C Spyropoulos, Maxine D Fisher, Larry E Fields, Roger M Mills, Judith J Stephenson, An-Chen Fu, Winslow Klaskala.   

Abstract

BACKGROUND: Hospitalized medically ill patients receiving antithrombotic medications experience increased risk of bleeding. We examined antithrombotic use, bleeding rates, and associated risk factors at 30 days post discharge.
METHODS: This retrospective database analysis included nonsurgical patients aged ≥40 years hospitalized for ≥2 days during 2005 to 2009. Previously cited, validated International Classification of Diseases, Ninth Revision, Clinical Modification codes for major bleeding were used to define clinically relevant bleeding.
RESULTS: Of the 327,578 patients, 9.1% received antithrombotic medications, of which 3.7% were anticoagulants. Rates of major and minor bleeding were 1.8% and 7.1%, respectively. Preindex gastroduodenal ulcer, thromboembolic stroke, blood dyscrasias, liver disease, and rehospitalization were the strongest predictors of major bleeding. Other risk factors included increasing age, male gender, and hospital stay of ≥3 days.
CONCLUSIONS: Careful consideration of these demonstrated bleed-associated comorbidities before initiating anticoagulation or combining antithrombotic medications in medically ill patients may improve strategies for prevention of postdischarge thromboembolism.

Entities:  

Keywords:  anticoagulants; antiplatelet; bleeding; drugs; thrombosis prophylaxis; venous thromboembolism

Mesh:

Substances:

Year:  2013        PMID: 23324537     DOI: 10.1177/1076029612470967

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  4 in total

1.  Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis.

Authors:  Andrea J Darzi; Samer G Karam; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Mary Cushman; Michael K Gould; Lawrence Mbuagbaw; Frederick A Spencer; Alex C Spyropoulos; Michael B Streiff; Scott Woller; Neil A Zakai; Federico Germini; Marta Rigoni; Arnav Agarwal; Rami Z Morsi; Alfonso Iorio; Elie A Akl; Holger J Schünemann
Journal:  Blood       Date:  2020-05-14       Impact factor: 22.113

Review 2.  Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.

Authors:  Scott Kaatz; Charles E Mahan; Asaad Nakhle; Kulothungan Gunasekaran; Mahmoud Ali; Robert Lavender; David G Paje
Journal:  Curr Cardiol Rep       Date:  2017-10-24       Impact factor: 2.931

Review 3.  Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.

Authors:  Allison E Burnett; Charles E Mahan; Sara R Vazquez; Lynn B Oertel; David A Garcia; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

4.  Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.

Authors:  Alex C Spyropoulos; Concetta Lipardi; Jianfeng Xu; Wentao Lu; Eunyoung Suh; Zhong Yuan; Bennett Levitan; Chiara Sugarmann; Yoriko De Sanctis; Theodore E Spiro; Elliot S Barnathan; Gary E Raskob
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.